Prevnar 20

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline, National Heart, Lung, and Blood Institute (NHLBI), Pfizer

Conditions

HealthyInfections, MeningococcalLymphomaPneumococcal InfectionsPneumonia, BacterialPneumonia, Pneumococcal

Phase 2

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

CompletedNCT05412030

GlaxoSmithKlinePneumococcal Infections, Pneumonia, Bacterial, Pneumonia, Pneumococcal

Start: 2022-06-16End: 2025-09-18Updated: 2025-10-21

Phase 3

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

CompletedNCT03621670

GlaxoSmithKlineInfections, Meningococcal

Start: 2018-07-27End: 2024-12-27Updated: 2026-02-10

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

RecruitingNCT07160244

Start: 2025-08-25End: 2029-03-02Target: 6000Updated: 2026-02-04

Phase 4

Vaccine Responses in Patients With B Cell Malignancies

RecruitingNCT05170399

National Heart, Lung, and Blood Institute (NHLBI)Lymphoma

Start: 2022-09-14End: 2026-08-16Target: 500Updated: 2026-02-05

Related Papers

408. Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine (PCV13) Administered Concomitantly with Routine Infant Vaccines (RIVs) to Healthy United States (US) Infants: A Randomized Controlled Study

Open Forum Infectious Diseases2026-01-01